Tapering and discontinuation of Avastin (bevacizumab)

Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma

Click here to view abstract

"These data indicate that tapering and discontinuation of bevacizumab therapy for other reasons than progression is feasible without an increased risk for tumor rebound or unresponsiveness to reinitiated bevacizumab therapy."

"Stable disease or partial response according to RANO at ≥3 months was achieved in 89 % of patients with reinitiated bevacizumab therapy after discontinuation."

I've uploaded this important study to folder 1 of the Library, Avastin subfolder.